Stephane Bancel

Stephane_Bancel

Stephane Bancel

Chief Executive Officer, Moderna Therapeutics

Stéphane joined Moderna in the summer of 2011 when it was a one employee and one patent company, after Dr. Noubar Afeyan and the board described to him the technology behind messenger RNA Therapeutics™. He has assembled a world-class team and raised the company’s financing.

He was previously CEO of bioMérieux, a world leader in the diagnostics industry. bioMerieux has more than 6,000 employees, a market capitalization of €2.5 billion, and sales of more than €1.3 billion. During his five years with bioMérieux, he accelerated the company’s sales growth rate from a historic rate of 4-5% per year to above 9% per year, grew EBIT at 12% CAGR (versus a historical growth rate of 4-5%), enhanced its position as the global leader in clinical microbiology and re-accelerated its immuno-assay franchise by focusing on high medical value biomarkers. He led the company through 10 successful acquisitions in the U.S., Europe, and Asia/Pacific without needing new capital from shareholders. During that time, the company’s market capitalization nearly doubled despite the 2008 financial crisis.

Prior to his time at bioMérieux, Stéphane was managing director of Eli Lilly in Belgium and executive director of global manufacturing strategy and supply chain at Eli Lilly in Indianapolis, Indiana. He started at Lilly in their UK manufacturing plant outside London.

He holds a Master of Engineering from École Central Paris, a Master of Science in Chemical Engineering from the University of Minnesota and an MBA from Harvard Business School.

Stéphane is named as an inventor on over 45 patent filings in the field of messenger RNA technology. These filings include claims covering a broad range of novel compositions and formulations as well as manufacturing and clinical methods in the fields of human and animal therapeutics, diagnostics and cell processing.

Stéphane was elected a 2009 Young Global Leader by the World Economic Forum. He was elected best CEO for investor relations in France in 2009 and was ranked the number one CEO in the biotech sector according to the 2011 Thomson Reuters EXTEL Study. Stephane serves as a supervisory director of Qiagen N.V., and on the Board of Directors of Syros Pharmaceuticals.

View More Exponential Medicine Faculty

Exponential Medicine brings together top experts to inform medical leaders how technology is impacting business. View the full list of 2015 faculty: